Department of Surgery, University of Calgary and the Foothills Medical Centre, Calgary, Alberta, Canada.
Crit Care Med. 2011 Dec;39(12):2743-51. doi: 10.1097/CCM.0b013e318228236f.
To summarize randomized controlled trials on the effects of sedative agents on neurologic outcome, mortality, intracranial pressure, cerebral perfusion pressure, and adverse drug events in critically ill adults with severe traumatic brain injury.
PubMed, MEDLINE, EMBASE, the Cochrane Database, Google Scholar, two clinical trials registries, personal files, and reference lists of included articles.
Randomized controlled trials of propofol, ketamine, etomidate, and agents from the opioid, benzodiazepine, α-2 agonist, and antipsychotic drug classes for management of adult intensive care unit patients with severe traumatic brain injury.
In duplicate and independently, two investigators extracted data and evaluated methodologic quality and results.
Among 1,892 citations, 13 randomized controlled trials enrolling 380 patients met inclusion criteria. Long-term sedation (≥24 hrs) was addressed in six studies, whereas a bolus dose, short infusion, or doubling of plasma drug concentration was investigated in remaining trials. Most trials did not describe baseline traumatic brain injury prognostic factors or important cointerventions. Eight trials possibly or definitely concealed allocation and six were blinded. Insufficient data exist regarding the effects of sedative agents on neurologic outcome or mortality. Although their effects are likely transient, bolus doses of opioids may increase intracranial pressure and decrease cerebral perfusion pressure. In one study, a long-term infusion of propofol vs. morphine was associated with a reduced requirement for intracranial pressure-lowering cointerventions and a lower intracranial pressure on the third day. Trials of propofol vs. midazolam and ketamine vs. sufentanil found no difference between agents in intracranial pressure and cerebral perfusion pressure.
This systematic review found no convincing evidence that one sedative agent is more efficacious than another for improvement of patient-centered outcomes, intracranial pressure, or cerebral perfusion pressure in critically ill adults with severe traumatic brain injury. High bolus doses of opioids, however, have potentially deleterious effects on intracranial pressure and cerebral perfusion pressure. Adequately powered, high-quality, randomized controlled trials are urgently warranted.
总结镇静剂对重症创伤性脑损伤成人神经功能结局、死亡率、颅内压、脑灌注压和药物不良事件影响的随机对照试验。
PubMed、MEDLINE、EMBASE、Cochrane 数据库、Google Scholar、两个临床试验注册处、个人文件和纳入文章的参考文献列表。
关于丙泊酚、氯胺酮、依托咪酯以及阿片类、苯二氮䓬类、α-2 激动剂和抗精神病药物类药物治疗重症监护成人创伤性脑损伤患者的随机对照试验。
在 1892 篇引用文献中,有 13 项随机对照试验纳入了 380 名患者,符合纳入标准。6 项研究探讨了长期镇静(≥24 小时),而其余研究则研究了单次剂量冲击、短时间输注或血浆药物浓度加倍。大多数试验没有描述基线创伤性脑损伤预后因素或重要的合并干预措施。8 项试验可能或明确隐瞒了分组,6 项试验设盲。关于镇静剂对神经功能结局或死亡率的影响,现有数据不足。尽管它们的作用可能是短暂的,但阿片类药物的单次剂量冲击可能会增加颅内压并降低脑灌注压。在一项研究中,与吗啡相比,丙泊酚的长期输注与降低需要降低颅内压的合并干预的需求以及第三天的颅内压降低相关。丙泊酚与咪达唑仑和氯胺酮与舒芬太尼的试验发现,两种药物在颅内压和脑灌注压方面没有差异。
本系统评价未发现令人信服的证据表明,与其他镇静剂相比,一种镇静剂在改善重症创伤性脑损伤成人患者的以患者为中心的结局、颅内压或脑灌注压方面更有效。然而,高剂量的阿片类药物可能对颅内压和脑灌注压有潜在的不良影响。迫切需要进行充分有力、高质量的随机对照试验。